Download PDF
Semin Liver Dis 2011; 31(2): 188-207
DOI: 10.1055/s-0031-1276647
© Thieme Medical Publishers

Deciphering the Genetic Predisposition to Primary Sclerosing Cholangitis

Tom H. Karlsen1 , Arthur Kaser2 , 3
  • 1Norwegian PSC Research Center, Clinic for Specialized Surgery and Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
  • 2Division of Gastroenterology and Hepatology, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
  • 3Department of Medicine II, Innsbruck Medical University, Innsbruck, Austria
Further Information

Publication History

Publication Date:
02 May 2011 (online)

    Permissions and Reprints

ABSTRACT

Genetic variants within the major histocompatibility complex (MHC) on chromosome 6 have been shown to confer risk for primary sclerosing cholangitis (PSC) ~30 years ago. However, robust genetic associations outside this genetic region have been difficult to establish. By genome-wide association analysis, a surprising large overlap of genetic risk loci outside of the MHC with prototypical autoimmune diseases has been recognized. In this article, we review the present knowledge of susceptibility loci in PSC, by assessing the robustness of the findings and speculating on potential mechanistic roles of predicted risk genes in PSC pathogenesis. We suggest a model where the primary insult is likely to resemble the tissue injury in most autoimmune conditions. Functional insight into risk pathways could offer novel therapeutic opportunities, and we speculate on specific opportunities that may arise based on current knowledge.

KEYWORDS

Primary sclerosing cholangitis - genetic predisposition - comorbidities - T lymphocytes - major histocompatibility complex

REFERENCES

  • 1 Karlsen T H, Schrumpf E, Boberg K M. Primary sclerosing cholangitis.  Best Pract Res Clin Gastroenterol. 2010;  24 (5) 655-666
    CrossrefPubMedGoogle Scholar
  • 2 European Association for the Study of the Liver . EASL clinical practice guidelines: management of cholestatic liver diseases.  J Hepatol. 2009;  51 (2) 237-267
    CrossrefPubMedGoogle Scholar
  • 3 Chapman R, Fevery J, Kalloo A American Association for the Study of Liver Diseases et al. Diagnosis and management of primary sclerosing cholangitis.  Hepatology. 2010;  51 (2) 660-678
    CrossrefPubMedGoogle Scholar
  • 4 Karlsen T H, Schrumpf E, Boberg K M. Update on primary sclerosing cholangitis.  Dig Liver Dis. 2010;  42 (6) 390-400
    CrossrefPubMedGoogle Scholar
  • 5 Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes.  Semin Liver Dis. 2007;  27 (1) 77-98
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Beuers U, Hohenester S, de Buy Wenniger L J, Kremer A E, Jansen P L, Elferink R P. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies.  Hepatology. 2010;  52 (4) 1489-1496
    CrossrefPubMedGoogle Scholar
  • 7 Lichtman S N, Keku J, Clark R L, Schwab J H, Sartor R B. Biliary tract disease in rats with experimental small bowel bacterial overgrowth.  Hepatology. 1991;  13 (4) 766-772
    CrossrefPubMedGoogle Scholar
  • 8 Grant A J, Lalor P F, Salmi M, Jalkanen S, Adams D H. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease.  Lancet. 2002;  359 (9301) 150-157
    CrossrefPubMedGoogle Scholar
  • 9 Terjung B, Söhne J, Lechtenberg B et al.. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ.  Gut. 2010;  59 (6) 808-816
    CrossrefPubMedGoogle Scholar
  • 10 O'Mahony C A, Vierling J M. Etiopathogenesis of primary sclerosing cholangitis.  Semin Liver Dis. 2006;  26 (1) 3-21
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Karlsen T H, Melum E, Franke A. The utility of genome-wide association studies in hepatology.  Hepatology. 2010;  51 (5) 1833-1842
    CrossrefPubMedGoogle Scholar
  • 12 Schrumpf E, Fausa O, Førre O, Dobloug J H, Ritland S, Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease.  Scand J Gastroenterol. 1982;  17 (2) 187-191
    CrossrefPubMedGoogle Scholar
  • 13 Karlsen T H, Franke A, Melum E et al.. Genome-wide association analysis in primary sclerosing cholangitis.  Gastroenterology. 2010;  138 (3) 1102-1111
    CrossrefPubMedGoogle Scholar
  • 14 Ludwig J. Surgical pathology of the syndrome of primary sclerosing cholangitis.  Am J Surg Pathol. 1989;  13 (Suppl 1) 43-49
    PubMedGoogle Scholar
  • 15 Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis.  Semin Liver Dis. 1991;  11 (1) 31-39
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Loftus Jr E V, Harewood G C, Loftus C G et al.. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.  Gut. 2005;  54 (1) 91-96
    CrossrefPubMedGoogle Scholar
  • 17 Saarinen S, Olerup O, Broomé U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis.  Am J Gastroenterol. 2000;  95 (11) 3195-3199
    CrossrefPubMedGoogle Scholar
  • 18 Zhernakova A, van Diemen C C, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases.  Nat Rev Genet. 2009;  10 (1) 43-55
    CrossrefPubMedGoogle Scholar
  • 19 Alvarez F, Berg P A, Bianchi F B et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol. 1999;  31 (5) 929-938
    CrossrefPubMedGoogle Scholar
  • 20 Blechacz B R, Sanchez W, Gores G J. A conceptual proposal for staging ductal cholangiocarcinoma.  Curr Opin Gastroenterol. 2009;  25 (3) 238-239
    CrossrefPubMedGoogle Scholar
  • 21 Karlsen T H, Hov J R. Genetics of cholestatic liver disease in 2010.  Curr Opin Gastroenterol. 2010;  26 (3) 251-258
    CrossrefPubMedGoogle Scholar
  • 22 Hindorff L A, Sethupathy P, Junkins H A et al.. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits.  Proc Natl Acad Sci U S A. 2009;  106 (23) 9362-9367
    CrossrefPubMedGoogle Scholar
  • 23 Boberg K M, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population.  Scand J Gastroenterol. 1998;  33 (1) 99-103
    CrossrefPubMedGoogle Scholar
  • 24 Bergquist A, Montgomery S M, Bahmanyar S et al.. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis.  Clin Gastroenterol Hepatol. 2008;  6 (8) 939-943
    CrossrefPubMedGoogle Scholar
  • 25 Manolio T A, Collins F S, Cox N J et al.. Finding the missing heritability of complex diseases.  Nature. 2009;  461 (7265) 747-753
    CrossrefPubMedGoogle Scholar
  • 26 Melum E, Franke A, Schramm C et al.. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci.  Nat Genet. 2011;  43 (1) 17-19
    CrossrefPubMedGoogle Scholar
  • 27 Clayton D G. Prediction and interaction in complex disease genetics: experience in type 1 diabetes.  PLoS Genet. 2009;  5 (7) e1000540
    CrossrefPubMedGoogle Scholar
  • 28 Lindor K D, Wiesner R H, Colwell L J, Steiner B, Beaver S, LaRusso N F. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis.  Am J Gastroenterol. 1991;  86 (1) 57-61
    PubMedGoogle Scholar
  • 29 Van Thiel D H, Carroll P, Abu-Elmagd K et al.. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial.  Am J Gastroenterol. 1995;  90 (3) 455-459
    PubMedGoogle Scholar
  • 30 Wiesner R H, Steiner B, LaRusso N F et al.. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis.  Hepatology. 1991;  14 A64 (Abstract)
    CrossrefPubMedGoogle Scholar
  • 31 Sandborn W J, Wiesner R H, Tremaine W J, Larusso N F. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin.  Gut. 1993;  34 (2) 242-246
    CrossrefPubMedGoogle Scholar
  • 32 Cullen S N, Chapman R W. The medical management of primary sclerosing cholangitis.  Semin Liver Dis. 2006;  26 (1) 52-61
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Boberg K M, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients.  Scand J Gastroenterol. 2003;  38 (9) 991-995
    CrossrefPubMedGoogle Scholar
  • 34 Lango Allen H, Estrada K, Lettre G et al.. Hundreds of variants clustered in genomic loci and biological pathways affect human height.  Nature. 2010;  457 832-838
    PubMedGoogle Scholar
  • 35 Traherne J A. Human MHC architecture and evolution: implications for disease association studies.  Int J Immunogenet. 2008;  35 (3) 179-192
    CrossrefPubMedGoogle Scholar
  • 36 Horton R, Wilming L, Rand V et al.. Gene map of the extended human MHC.  Nat Rev Genet. 2004;  5 (12) 889-899
    CrossrefPubMedGoogle Scholar
  • 37 de Bakker P I, McVean G, Sabeti P C et al.. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC.  Nat Genet. 2006;  38 (10) 1166-1172
    CrossrefPubMedGoogle Scholar
  • 38 Sollid L M, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer.  J Exp Med. 1989;  169 (1) 345-350
    CrossrefPubMedGoogle Scholar
  • 39 Todd J A, Bell J I, McDevitt H O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus.  Nature. 1987;  329 (6140) 599-604
    CrossrefPubMedGoogle Scholar
  • 40 Oksenberg J R, Barcellos L F, Cree B A et al.. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans.  Am J Hum Genet. 2004;  74 (1) 160-167
    CrossrefPubMedGoogle Scholar
  • 41 Schlosstein L, Terasaki P I, Bluestone R, Pearson C M. High association of an HL-A antigen, W27, with ankylosing spondylitis.  N Engl J Med. 1973;  288 (14) 704-706
    CrossrefPubMedGoogle Scholar
  • 42 Nair R P, Stuart P E, Nistor I et al.. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene.  Am J Hum Genet. 2006;  78 (5) 827-851
    CrossrefPubMedGoogle Scholar
  • 43 Lie B A, Thorsby E. Several genes in the extended human MHC contribute to predisposition to autoimmune diseases.  Curr Opin Immunol. 2005;  17 (5) 526-531
    CrossrefPubMedGoogle Scholar
  • 44 Nejentsev S, Howson J M, Walker N M Wellcome Trust Case Control Consortium et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A.  Nature. 2007;  450 (7171) 887-892
    CrossrefPubMedGoogle Scholar
  • 45 Fernando M M, Stevens C R, Walsh E C et al.. Defining the role of the MHC in autoimmunity: a review and pooled analysis.  PLoS Genet. 2008;  4 (4) e1000024
    CrossrefPubMedGoogle Scholar
  • 46 Rioux J D, Goyette P, Vyse T J International MHC and Autoimmunity Genetics Network et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases.  Proc Natl Acad Sci U S A. 2009;  106 (44) 18680-18685
    CrossrefPubMedGoogle Scholar
  • 47 The International HIV Controllers Study . The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.  Science. 2010;  330 (6010) 1551-1557
    CrossrefPubMedGoogle Scholar
  • 48 Karlsen T H, Boberg K M, Olsson M et al.. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis.  J Hepatol. 2007;  46 (5) 899-906
    CrossrefPubMedGoogle Scholar
  • 49 Hov J R, Lleo A, Selmi C et al.. Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C.  J Hepatol. 2010;  52 (5) 712-717
    CrossrefPubMedGoogle Scholar
  • 50 Hov J R, Boberg K M, Karlsen T H. Autoantibodies in primary sclerosing cholangitis.  World J Gastroenterol. 2008;  14 (24) 3781-3791
    CrossrefPubMedGoogle Scholar
  • 51 van Heel D A, Franke L, Hunt K A et al.. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21.  Nat Genet. 2007;  39 (7) 827-829
    CrossrefPubMedGoogle Scholar
  • 52 Festen E A, Goyette P, Scott R et al.. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis.  Gut. 2009;  58 (6) 799-804
    Google Scholar
  • 53 Hollis-Moffatt J E, Chen-Xu M, Topless R et al.. Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2–IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance.  Arthritis Res Ther. 2010;  12 (3) R116
    CrossrefPubMedGoogle Scholar
  • 54 Todd J A, Walker N M, Cooper J D Genetics of Type 1 Diabetes in Finland et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes.  Nat Genet. 2007;  39 (7) 857-864
    CrossrefPubMedGoogle Scholar
  • 55 Janse M, Lamberts L E, Franke L et al.. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL and CARS9.  [Epub ahead of print]
    PubMedGoogle Scholar
  • 56 Vella A, Cooper J D, Lowe C E et al.. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms.  Am J Hum Genet. 2005;  76 (5) 773-779
    CrossrefPubMedGoogle Scholar
  • 57 Franke A, McGovern D P, Barrett J C et al.. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.  Nat Genet. 2010;  42 (12) 1118-1125
    CrossrefPubMedGoogle Scholar
  • 58 Anderson C A, Boucher G, Lees C W et al.. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.  Nat Genet. 2011;  43 (3) 246-252
    Google Scholar
  • 59 Qu H Q, Bradfield J P, Bélisle A, Grant S F, Hakonarson H, Polychronakos C. Type I Diabetes Genetics Consortium . The type I diabetes association of the IL2RA locus.  Genes Immun. 2009;  10 (Suppl 1) S42-S48
    CrossrefPubMedGoogle Scholar
  • 60 Lowe C E, Cooper J D, Brusko T et al.. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.  Nat Genet. 2007;  39 (9) 1074-1082
    CrossrefPubMedGoogle Scholar
  • 61 Perera D, Stankovich J, Butzkueven H et al.. Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus.  J Neuroimmunol. 2009;  211 (1–2) 105-109
    CrossrefPubMedGoogle Scholar
  • 62 Qu H Q, Verlaan D J, Ge B et al.. A cis-acting regulatory variant in the IL2RA locus.  J Immunol. 2009;  183 (8) 5158-5162
    CrossrefPubMedGoogle Scholar
  • 63 Dendrou C A, Plagnol V, Fung E et al.. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource.  Nat Genet. 2009;  41 (9) 1011-1015
    CrossrefPubMedGoogle Scholar
  • 64 Malek T R, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity.  Immunity. 2010;  33 (2) 153-165
    CrossrefPubMedGoogle Scholar
  • 65 Yamanouchi J, Rainbow D, Serra P et al.. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity.  Nat Genet. 2007;  39 (3) 329-337
    CrossrefPubMedGoogle Scholar
  • 66 Wakabayashi K, Lian Z X, Moritoki Y et al.. IL-2 receptor alpha( − / − ) mice and the development of primary biliary cirrhosis.  Hepatology. 2006;  44 (5) 1240-1249
    CrossrefPubMedGoogle Scholar
  • 67 Sadlack B, Merz H, Schorle H, Schimpl A, Feller A C, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.  Cell. 1993;  75 (2) 253-261
    CrossrefPubMedGoogle Scholar
  • 68 Willerford D M, Chen J, Ferry J A, Davidson L, Ma A, Alt F W. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment.  Immunity. 1995;  3 (4) 521-530
    CrossrefPubMedGoogle Scholar
  • 69 Hsu W, Zhang W, Tsuneyama K et al.. Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha( − / − ) mice.  Hepatology. 2009;  49 (1) 133-140
    CrossrefPubMedGoogle Scholar
  • 70 Zhang W, Sharma R, Ju S T et al.. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis.  Hepatology. 2009;  49 (2) 545-552
    CrossrefPubMedGoogle Scholar
  • 71 Fontenot J D, Rudensky A Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.  Nat Immunol. 2005;  6 (4) 331-337
    CrossrefPubMedGoogle Scholar
  • 72 Hirschfield G M, Liu X, Xu C et al.. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants.  N Engl J Med. 2009;  360 (24) 2544-2555
    CrossrefPubMedGoogle Scholar
  • 73 Hirschfield G M, Liu X, Han Y et al.. Variants at IRF5-TNPO3, 17q12–21 and MMEL1 are associated with primary biliary cirrhosis.  Nat Genet. 2010;  42 (8) 655-657
    CrossrefPubMedGoogle Scholar
  • 74 Liu X, Invernizzi P, Lu Y et al.. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis.  Nat Genet. 2010;  42 (8) 658-660
    CrossrefPubMedGoogle Scholar
  • 75 Irie J, Wu Y, Wicker L S et al.. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis.  J Exp Med. 2006;  203 (5) 1209-1219
    CrossrefPubMedGoogle Scholar
  • 76 Coquet J M, Kyparissoudis K, Pellicci D G et al.. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production.  J Immunol. 2007;  178 (5) 2827-2834
    PubMedGoogle Scholar
  • 77 Spolski R, Leonard W J. Interleukin-21: basic biology and implications for cancer and autoimmunity.  Annu Rev Immunol. 2008;  26 57-79
    CrossrefPubMedGoogle Scholar
  • 78 Parrish-Novak J, Dillon S R, Nelson A et al.. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.  Nature. 2000;  408 (6808) 57-63
    CrossrefPubMedGoogle Scholar
  • 79 Nurieva R, Yang X O, Martinez G et al.. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells.  Nature. 2007;  448 (7152) 480-483
    CrossrefPubMedGoogle Scholar
  • 80 Korn T, Bettelli E, Gao W et al.. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.  Nature. 2007;  448 (7152) 484-487
    CrossrefPubMedGoogle Scholar
  • 81 Zhou L, Ivanov I I, Spolski R et al.. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.  Nat Immunol. 2007;  8 (9) 967-974
    CrossrefPubMedGoogle Scholar
  • 82 Nurieva R I, Chung Y, Martinez G J et al.. Bcl6 mediates the development of T follicular helper cells.  Science. 2009;  325 (5943) 1001-1005
    CrossrefPubMedGoogle Scholar
  • 83 Zeng R, Spolski R, Finkelstein S E et al.. Synergy of IL-21 and IL-15 in regulating CD8 + T cell expansion and function.  J Exp Med. 2005;  201 (1) 139-148
    CrossrefPubMedGoogle Scholar
  • 84 Ozaki K, Spolski R, Feng C G et al.. A critical role for IL-21 in regulating immunoglobulin production.  Science. 2002;  298 (5598) 1630-1634
    CrossrefPubMedGoogle Scholar
  • 85 Jin H, Carrio R, Yu A, Malek T R. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis.  J Immunol. 2004;  173 (1) 657-665
    PubMedGoogle Scholar
  • 86 Mehta D S, Wurster A L, Whitters M J, Young D A, Collins M, Grusby M J. IL-21 induces the apoptosis of resting and activated primary B cells.  J Immunol. 2003;  170 (8) 4111-4118
    PubMedGoogle Scholar
  • 87 Ozaki K, Spolski R, Ettinger R et al.. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6.  J Immunol. 2004;  173 (9) 5361-5371
    PubMedGoogle Scholar
  • 88 Herber D, Brown T P, Liang S, Young D A, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.  J Immunol. 2007;  178 (6) 3822-3830
    PubMedGoogle Scholar
  • 89 Vollmer T L, Liu R, Price M, Rhodes S, La Cava A, Shi F D. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen.  J Immunol. 2005;  174 (5) 2696-2701
    PubMedGoogle Scholar
  • 90 Oh I, Ozaki K, Meguro A et al.. Altered effector CD4 + T cell function in IL-21R − / − CD4 + T cell-mediated graft-versus-host disease.  J Immunol. 2010;  185 (3) 1920-1926
    CrossrefPubMedGoogle Scholar
  • 91 Morton L M, Purdue M P, Zheng T et al.. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.  Cancer Epidemiol Biomarkers Prev. 2009;  18 (4) 1259-1270
    CrossrefPubMedGoogle Scholar
  • 92 Man K M, Drejet A, Keeffe E B, Garcia-Kennedy R, Imperial J C, Esquivel C O. Primary sclerosing cholangitis and Hodgkin's disease.  Hepatology. 1993;  18 (5) 1127-1131
    CrossrefPubMedGoogle Scholar
  • 93 Cholongitas E, Pipili C, Kaklamanis L, Dasenaki M. Is there any association between non-Hodgkin's lymphoma and primary sclerosing cholangitis/autoimmune hepatitis overlap syndrome?.  Dig Dis Sci. 2008;  53 (3) 867-868
    CrossrefPubMedGoogle Scholar
  • 94 Strasser A. The role of BH3-only proteins in the immune system.  Nat Rev Immunol. 2005;  5 (3) 189-200
    CrossrefPubMedGoogle Scholar
  • 95 Bouillet P, Metcalf D, Huang D C et al.. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity.  Science. 1999;  286 (5445) 1735-1738
    CrossrefPubMedGoogle Scholar
  • 96 Hildeman D A, Zhu Y, Mitchell T C et al.. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim.  Immunity. 2002;  16 (6) 759-767
    CrossrefPubMedGoogle Scholar
  • 97 Puthalakath H, O'Reilly L A, Gunn P et al.. ER stress triggers apoptosis by activating BH3-only protein Bim.  Cell. 2007;  129 (7) 1337-1349
    CrossrefPubMedGoogle Scholar
  • 98 Satsangi J, Parkes M, Louis E et al.. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12.  Nat Genet. 1996;  14 (2) 199-202
    CrossrefPubMedGoogle Scholar
  • 99 Raelson J V, Little R D, Ruether A et al.. Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci.  Proc Natl Acad Sci U S A. 2007;  104 (37) 14747-14752
    CrossrefPubMedGoogle Scholar
  • 100 Goyette P, Lefebvre C, Ng A et al.. Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis.  Mucosal Immunol. 2008;  1 (2) 131-138
    CrossrefPubMedGoogle Scholar
  • 101 Esworthy R S, Aranda R, Martín M G, Doroshow J H, Binder S W, Chu F F. Mice with combined disruption of Gpx1 and Gpx2 genes have colitis.  Am J Physiol Gastrointest Liver Physiol. 2001;  281 (3) G848-G855
    PubMedGoogle Scholar
  • 102 Beckly J B, Hancock L, Geremia A et al.. Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn's disease.  Inflamm Bowel Dis. 2008;  14 (4) 500-507
    CrossrefPubMedGoogle Scholar
  • 103 Hunt K A, Zhernakova A, Turner G et al.. Newly identified genetic risk variants for celiac disease related to the immune response.  Nat Genet. 2008;  40 (4) 395-402
    CrossrefPubMedGoogle Scholar
  • 104 Yoshimura T, Yuhki N, Wang M H, Skeel A, Leonard E J. Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3.  J Biol Chem. 1993;  268 (21) 15461-15468
    PubMedGoogle Scholar
  • 105 Wang M H, Skeel A, Leonard E J. Proteolytic cleavage and activation of pro-macrophage-stimulating protein by resident peritoneal macrophage membrane proteases.  J Clin Invest. 1996;  97 (3) 720-727
    CrossrefPubMedGoogle Scholar
  • 106 Bezerra J A, Carrick T L, Degen J L, Witte D, Degen S J. Biological effects of targeted inactivation of hepatocyte growth factor-like protein in mice.  J Clin Invest. 1998;  101 (5) 1175-1183
    CrossrefPubMedGoogle Scholar
  • 107 Gaudino G, Follenzi A, Naldini L et al.. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP.  EMBO J. 1994;  13 (15) 3524-3532
    PubMedGoogle Scholar
  • 108 Wang M H, Dlugosz A A, Sun Y, Suda T, Skeel A, Leonard E J. Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes.  Exp Cell Res. 1996;  226 (1) 39-46
    CrossrefPubMedGoogle Scholar
  • 109 Wang M H, Ronsin C, Gesnel M C et al.. Identification of the ron gene product as the receptor for the human macrophage stimulating protein.  Science. 1994;  266 (5182) 117-119
    CrossrefPubMedGoogle Scholar
  • 110 Kurihara N, Iwama A, Tatsumi J, Ikeda K, Suda T. Macrophage-stimulating protein activates STK receptor tyrosine kinase on osteoclasts and facilitates bone resorption by osteoclast-like cells.  Blood. 1996;  87 (9) 3704-3710
    PubMedGoogle Scholar
  • 111 Goyette P, Lefebvre C, Ng A et al.. Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis.  Mucosal Immunol. 2008;  1 (2) 131-138
    CrossrefPubMedGoogle Scholar
  • 112 Morrison A C, Wilson C B, Ray M, Correll P H. Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide.  J Immunol. 2004;  172 (3) 1825-1832
    PubMedGoogle Scholar
  • 113 Chen Y Q, Fisher J H, Wang M H. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression.  J Immunol. 1998;  161 (9) 4950-4959
    PubMedGoogle Scholar
  • 114 Zhou Y Q, Chen Y Q, Fisher J H, Wang M H. Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages.  J Biol Chem. 2002;  277 (41) 38104-38110
    CrossrefPubMedGoogle Scholar
  • 115 Liu Q P, Fruit K, Ward J, Correll P H. Negative regulation of macrophage activation in response to IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase.  J Immunol. 1999;  163 (12) 6606-6613
    PubMedGoogle Scholar
  • 116 Correll P H, Iwama A, Tondat S, Mayrhofer G, Suda T, Bernstein A. Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase.  Genes Funct. 1997;  1 (1) 69-83
    CrossrefPubMedGoogle Scholar
  • 117 Lei X G, Cheng W H. New roles for an old selenoenzyme: evidence from glutathione peroxidase-1 null and overexpressing mice.  J Nutr. 2005;  135 (10) 2295-2298
    PubMedGoogle Scholar
  • 118 Esworthy R S, Binder S W, Doroshow J H, Chu F F. Microflora trigger colitis in mice deficient in selenium-dependent glutathione peroxidase and induce Gpx2 gene expression.  Biol Chem. 2003;  384 (4) 597-607
    CrossrefPubMedGoogle Scholar
  • 119 Gao Q, Esworthy R S, Kim B W, Synold T W, Smith D D, Chu F F. Atherogenic diets exacerbate colitis in mice deficient in glutathione peroxidase.  Inflamm Bowel Dis. 2010;  16 (12) 2043-2054
    CrossrefPubMedGoogle Scholar
  • 120 Todd D J, Lee A H, Glimcher L H. The endoplasmic reticulum stress response in immunity and autoimmunity.  Nat Rev Immunol. 2008;  8 (9) 663-674
    CrossrefPubMedGoogle Scholar
  • 121 Kaser A, Lee A H, Franke A et al.. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease.  Cell. 2008;  134 (5) 743-756
    CrossrefPubMedGoogle Scholar
  • 122 Fickert P, Zollner G, Fuchsbichler A et al.. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.  Gastroenterology. 2001;  121 (1) 170-183
    CrossrefPubMedGoogle Scholar
  • 123 Lee D H, Esworthy R S, Chu C, Pfeifer G P, Chu F F. Mutation accumulation in the intestine and colon of mice deficient in two intracellular glutathione peroxidases.  Cancer Res. 2006;  66 (20) 9845-9851
    CrossrefPubMedGoogle Scholar
  • 124 Chu F F, Esworthy R S, Chu P G et al.. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes.  Cancer Res. 2004;  64 (3) 962-968
    CrossrefPubMedGoogle Scholar
  • 125 Loh K, Deng H, Fukushima A et al.. Reactive oxygen species enhance insulin sensitivity.  Cell Metab. 2009;  10 (4) 260-272
    CrossrefPubMedGoogle Scholar
  • 126 Franke A, Balschun T, Karlsen T H IBSEN study group et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility.  Nat Genet. 2008;  40 (11) 1319-1323
    CrossrefPubMedGoogle Scholar
  • 127 Hov J R, Keitel V, Laerdahl J K IBSEN Study Group et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis.  PLoS ONE. 2010;  5 (8) e12403
    CrossrefPubMedGoogle Scholar
  • 128 Hov J R, Keitel V, Laerdahl J K IBSEN Study Group et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis.  PLoS ONE. 2010;  5 (8) e12403
    CrossrefPubMedGoogle Scholar
  • 129 Kawamata Y, Fujii R, Hosoya M et al.. A G protein-coupled receptor responsive to bile acids.  J Biol Chem. 2003;  278 (11) 9435-9440
    CrossrefPubMedGoogle Scholar
  • 130 Keitel V, Donner M, Winandy S, Kubitz R, Häussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells.  Biochem Biophys Res Commun. 2008;  372 (1) 78-84
    CrossrefPubMedGoogle Scholar
  • 131 Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.  Trends Pharmacol Sci. 2009;  30 (11) 570-580
    CrossrefPubMedGoogle Scholar
  • 132 Watanabe M, Houten S M, Mataki C et al.. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.  Nature. 2006;  439 (7075) 484-489
    CrossrefPubMedGoogle Scholar
  • 133 Thomas C, Gioiello A, Noriega L et al.. TGR5-mediated bile acid sensing controls glucose homeostasis.  Cell Metab. 2009;  10 (3) 167-177
    CrossrefPubMedGoogle Scholar
  • 134 Chhabra E S, Higgs H N. The many faces of actin: matching assembly factors with cellular structures.  Nat Cell Biol. 2007;  9 (10) 1110-1121
    CrossrefPubMedGoogle Scholar
  • 135 Pollard T D. Regulation of actin filament assembly by Arp2/3 complex and formins.  Annu Rev Biophys Biomol Struct. 2007;  36 451-477
    CrossrefPubMedGoogle Scholar
  • 136 Gournier H, Goley E D, Niederstrasser H, Trinh T, Welch M D. Reconstitution of human Arp2/3 complex reveals critical roles of individual subunits in complex structure and activity.  Mol Cell. 2001;  8 (5) 1041-1052
    CrossrefPubMedGoogle Scholar
  • 137 Robinson R C, Turbedsky K, Kaiser D A et al.. Crystal structure of Arp2/3 complex.  Science. 2001;  294 (5547) 1679-1684
    CrossrefPubMedGoogle Scholar
  • 138 Padrick S B, Rosen M K. Physical mechanisms of signal integration by WASP family proteins.  Annu Rev Biochem. 2010;  79 707-735
    CrossrefPubMedGoogle Scholar
  • 139 Cai L, Marshall T W, Uetrecht A C, Schafer D A, Bear J E. Coronin 1B coordinates Arp2/3 complex and cofilin activities at the leading edge.  Cell. 2007;  128 (5) 915-929
    CrossrefPubMedGoogle Scholar
  • 140 Shiow L R, Roadcap D W, Paris K et al.. The actin regulator coronin 1A is mutant in a thymic egress-deficient mouse strain and in a patient with severe combined immunodeficiency.  Nat Immunol. 2008;  9 (11) 1307-1315
    CrossrefPubMedGoogle Scholar
  • 141 Cotta-de-Almeida V, Westerberg L, Maillard M H et al.. Wiskott Aldrich syndrome protein (WASP) and N-WASP are critical for T cell development.  Proc Natl Acad Sci U S A. 2007;  104 (39) 15424-15429
    CrossrefPubMedGoogle Scholar
  • 142 Maillard M H, Cotta-de-Almeida V, Takeshima F et al.. The Wiskott-Aldrich syndrome protein is required for the function of CD4( + )CD25( + )Foxp3( + ) regulatory T cells.  J Exp Med. 2007;  204 (2) 381-391
    CrossrefPubMedGoogle Scholar
  • 143 Nguyen D D, Maillard M H, Cotta-de-Almeida V et al.. Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein.  Gastroenterology. 2007;  133 (4) 1188-1197
    CrossrefPubMedGoogle Scholar
  • 144 Ramesh N, Geha R. Recent advances in the biology of WASP and WIP.  Immunol Res. 2009;  44 (1–3) 99-111
    CrossrefPubMedGoogle Scholar
  • 145 Lambrechts A, Gevaert K, Cossart P, Vandekerckhove J, Van Troys M. Listeria comet tails: the actin-based motility machinery at work.  Trends Cell Biol. 2008;  18 (5) 220-227
    CrossrefPubMedGoogle Scholar
  • 146 Waugh D J, Wilson C. The interleukin-8 pathway in cancer.  Clin Cancer Res. 2008;  14 (21) 6735-6741
    CrossrefPubMedGoogle Scholar
  • 147 Stillie R, Farooq S M, Gordon J R, Stadnyk A W. The functional significance behind expressing two IL-8 receptor types on PMN.  J Leukoc Biol. 2009;  86 (3) 529-543
    CrossrefPubMedGoogle Scholar
  • 148 Isse K, Harada K, Nakanuma Y. IL-8 expression by biliary epithelial cells is associated with neutrophilic infiltration and reactive bile ductules.  Liver Int. 2007;  27 (5) 672-680
    CrossrefPubMedGoogle Scholar
  • 149 Komori A, Nakamura M, Fujiwara S et al.. Human intrahepatic biliary epithelial cell as a possible modulator of hepatic regeneration: Potential role of biliary epithelial cell for hepatic remodeling in vivo.  Hepatol Res. 2007;  37 (Suppl 3) S438-S443
    CrossrefPubMedGoogle Scholar
  • 150 Balkwill F. Cancer and the chemokine network.  Nat Rev Cancer. 2004;  4 (7) 540-550
    CrossrefPubMedGoogle Scholar
  • 151 Agarwal A, Tressel S L, Kaimal R et al.. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy.  Cancer Res. 2010;  70 (14) 5880-5890
    CrossrefPubMedGoogle Scholar
  • 152 Baranzini S E, Wang J, Gibson R A et al.. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis.  Hum Mol Genet. 2009;  18 (4) 767-778
    PubMedGoogle Scholar
  • 153 Comabella M, Craig D W, Camiña-Tato M BiomarkerMS Study Group et al. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms.  PLoS ONE. 2008;  3 (10) e3490
    CrossrefPubMedGoogle Scholar
  • 154 Cénit M D, Blanco-Kelly F, de las Heras V et al.. Glypican 5 is an interferon-beta response gene: a replication study.  Mult Scler. 2009;  15 (8) 913-917
    CrossrefPubMedGoogle Scholar
  • 155 Okada Y, Kamatani Y, Takahashi A et al.. A genome-wide association study in 19 633 Japanese subjects identified LHX3-QSOX2 and IGF1 as adult height loci.  Hum Mol Genet. 2010;  19 (11) 2303-2312
    CrossrefPubMedGoogle Scholar
  • 156 Calboli F C, Tozzi F, Galwey N W et al.. A genome-wide association study of neuroticism in a population-based sample.  PLoS ONE. 2010;  5 (7) e11504
    CrossrefPubMedGoogle Scholar
  • 157 Lesch K P, Timmesfeld N, Renner T J et al.. Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies.  J Neural Transm. 2008;  115 (11) 1573-1585
    CrossrefPubMedGoogle Scholar
  • 158 Li Y, Sheu C C, Ye Y et al.. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study.  Lancet Oncol. 2010;  11 (4) 321-330
    CrossrefPubMedGoogle Scholar
  • 159 Pelak K, Goldstein D B, Walley N M Infectious Disease Clinical Research Program HIV Working Group et al. Host determinants of HIV-1 control in African Americans.  J Infect Dis. 2010;  201 (8) 1141-1149
    CrossrefPubMedGoogle Scholar
  • 160 Filmus J, Capurro M, Rast J. Glypicans.  Genome Biol. 2008;  9 (5) 224
    CrossrefPubMedGoogle Scholar
  • 161 Veugelers M, Vermeesch J, Reekmans G, Steinfeld R, Marynen P, David G. Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family.  Genomics. 1997;  40 (1) 24-30
    CrossrefPubMedGoogle Scholar
  • 162 Saunders S, Paine-Saunders S, Lander A D. Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain.  Dev Biol. 1997;  190 (1) 78-93
    CrossrefPubMedGoogle Scholar
  • 163 Veugelers M, De Cat B, Ceulemans H et al.. Glypican-6, a new member of the glypican family of cell surface heparan sulfate proteoglycans.  J Biol Chem. 1999;  274 (38) 26968-26977
    CrossrefPubMedGoogle Scholar
  • 164 Paine-Saunders S, Viviano B L, Saunders S. GPC6, a novel member of the glypican gene family, encodes a product structurally related to GPC4 and is colocalized with GPC5 on human chromosome 13.  Genomics. 1999;  57 (3) 455-458
    CrossrefPubMedGoogle Scholar
  • 165 Campos-Xavier A B, Martinet D, Bateman J et al.. Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia.  Am J Hum Genet. 2009;  84 (6) 760-770
    CrossrefPubMedGoogle Scholar
  • 166 Gregersen P K, Amos C I, Lee A T et al.. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis.  Nat Genet. 2009;  41 (7) 820-823
    CrossrefPubMedGoogle Scholar
  • 167 Dubois P C, Trynka G, Franke L et al.. Multiple common variants for celiac disease influencing immune gene expression.  Nat Genet. 2010;  42 (4) 295-302
    CrossrefPubMedGoogle Scholar
  • 168 McGovern D P, Gardet A, Törkvist L NIDDK IBD Genetics Consortium et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci.  Nat Genet. 2010;  42 (4) 332-337
    CrossrefPubMedGoogle Scholar
  • 169 Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system.  Annu Rev Immunol. 2009;  27 693-733
    CrossrefPubMedGoogle Scholar
  • 170 Liou H C, Hsia C Y. Distinctions between c-Rel and other NF-kappaB proteins in immunity and disease.  Bioessays. 2003;  25 (8) 767-780
    CrossrefPubMedGoogle Scholar
  • 171 Hilliard B A, Mason N, Xu L et al.. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation.  J Clin Invest. 2002;  110 (6) 843-850
    PubMedGoogle Scholar
  • 172 Köntgen F, Grumont R J, Strasser A et al.. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression.  Genes Dev. 1995;  9 (16) 1965-1977
    CrossrefPubMedGoogle Scholar
  • 173 Long M, Park S G, Strickland I, Hayden M S, Ghosh S. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor.  Immunity. 2009;  31 (6) 921-931
    CrossrefPubMedGoogle Scholar
  • 174 Rao S, Gerondakis S, Woltring D, Shannon M F. c-Rel is required for chromatin remodeling across the IL-2 gene promoter.  J Immunol. 2003;  170 (7) 3724-3731
    PubMedGoogle Scholar
  • 175 Chen G, Hardy K, Bunting K, Daley S, Ma L, Shannon M F. Regulation of the IL-21 gene by the NF-kappaB transcription factor c-Rel.  J Immunol. 2010;  185 (4) 2350-2359
    CrossrefPubMedGoogle Scholar
  • 176 Grossmann M, O'Reilly L A, Gugasyan R, Strasser A, Adams J M, Gerondakis S. The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression.  EMBO J. 2000;  19 (23) 6351-6360
    CrossrefPubMedGoogle Scholar
  • 177 Pohl T, Gugasyan R, Grumont R J et al.. The combined absence of NF-kappa B1 and c-Rel reveals that overlapping roles for these transcription factors in the B cell lineage are restricted to the activation and function of mature cells.  Proc Natl Acad Sci U S A. 2002;  99 (7) 4514-4519
    CrossrefPubMedGoogle Scholar
  • 178 Gieling R G, Elsharkawy A M, Caamaño J H et al.. The c-Rel subunit of nuclear factor-kappaB regulates murine liver inflammation, wound-healing, and hepatocyte proliferation.  Hepatology. 2010;  51 (3) 922-931
    CrossrefPubMedGoogle Scholar
  • 179 Raychaudhuri S, Plenge R M, Rossin E J International Schizophrenia Consortium et al. Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions.  PLoS Genet. 2009;  5 (6) e1000534
    CrossrefPubMedGoogle Scholar
  • 180 Mamanova L, Coffey A J, Scott C E et al.. Target-enrichment strategies for next-generation sequencing.  Nat Methods. 2010;  7 (2) 111-118
    CrossrefPubMedGoogle Scholar
  • 181 Melum E, May S, Schilhabel M B et al.. SNP discovery performance of two second-generation sequencing platforms in the NOD2 gene region.  Hum Mutat. 2010;  31 (7) 875-885
    CrossrefPubMedGoogle Scholar
  • 182 Kaser A, Zeissig S, Blumberg R S. Inflammatory bowel disease.  Annu Rev Immunol. 2010;  28 573-621
    CrossrefPubMedGoogle Scholar
  • 183 Probert C S, Christ A D, Saubermann L J et al.. Analysis of human common bile duct-associated T cells: evidence for oligoclonality, T cell clonal persistence, and epithelial cell recognition.  J Immunol. 1997;  158 (4) 1941-1948
    PubMedGoogle Scholar
  • 184 Broomé U, Grunewald J, Scheynius A, Olerup O, Hultcrantz R. Preferential V beta3 usage by hepatic T lymphocytes in patients with primary sclerosing cholangitis.  J Hepatol. 1997;  26 (3) 527-534
    PubMedGoogle Scholar
  • 185 Graziadei I W, Wiesner R H, Batts K P et al.. Recurrence of primary sclerosing cholangitis following liver transplantation.  Hepatology. 1999;  29 (4) 1050-1056
    CrossrefPubMedGoogle Scholar
  • 186 Kugelmas M, Spiegelman P, Osgood M J et al.. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation.  Liver Transpl. 2003;  9 (7) 727-732
    CrossrefPubMedGoogle Scholar
  • 187 Liu J O. Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation.  Immunol Rev. 2009;  228 (1) 184-198
    CrossrefPubMedGoogle Scholar
  • 188 Todd J A. Etiology of type 1 diabetes.  Immunity. 2010;  32 (4) 457-467
    CrossrefPubMedGoogle Scholar
  • 189 Tang Q, Adams J Y, Penaranda C et al.. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.  Immunity. 2008;  28 (5) 687-697
    CrossrefPubMedGoogle Scholar
  • 190 Nejentsev S, Walker N, Riches D, Egholm M, Todd J A. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes.  Science. 2009;  324 (5925) 387-389
    CrossrefPubMedGoogle Scholar
  • 191 Smyth D J, Cooper J D, Bailey R et al.. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region.  Nat Genet. 2006;  38 (6) 617-619
    CrossrefPubMedGoogle Scholar
  • 192 Kato H, Takeuchi O, Sato S et al.. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.  Nature. 2006;  441 (7089) 101-105
    CrossrefPubMedGoogle Scholar
  • 193 Dotta F, Censini S, van Halteren A G et al.. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients.  Proc Natl Acad Sci U S A. 2007;  104 (12) 5115-5120
    CrossrefPubMedGoogle Scholar
  • 194 Boberg K M, Bergquist A, Mitchell S et al.. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.  Scand J Gastroenterol. 2002;  37 (10) 1205-1211
    CrossrefPubMedGoogle Scholar
  • 195 Donaldson P T, Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis.  Autoimmunity. 2002;  35 (8) 555-564
    CrossrefPubMedGoogle Scholar
  • 196 Donaldson P T, Norris S. Immunogenetics in PSC.  Best Pract Res Clin Gastroenterol. 2001;  15 (4) 611-627
    CrossrefPubMedGoogle Scholar
  • 197 Zhao B, Schlesiger C, Masucci M G, Lindsten K. The ubiquitin specific protease 4 (USP4) is a new player in the Wnt signalling pathway.  J Cell Mol Med. 2009;  13 (8B) 1886-1895
    CrossrefPubMedGoogle Scholar
  • 198 Zhou Q, Hennenberg M, Trebicka J et al.. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.  Gut. 2006;  55 (9) 1296-1305
    CrossrefPubMedGoogle Scholar
  • 199 Debruyne P R, Bruyneel E A, Karaguni I M et al.. Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways.  Oncogene. 2002;  21 (44) 6740-6750
    CrossrefPubMedGoogle Scholar
  • 200 Applegarth D A, Toone J R. Glycine encephalopathy (nonketotic hyperglycinaemia): review and update.  J Inherit Metab Dis. 2004;  27 (3) 417-422
    CrossrefPubMedGoogle Scholar
  • 201 Barresi R, Campbell K P. Dystroglycan: from biosynthesis to pathogenesis of human disease.  J Cell Sci. 2006;  119 (Pt 2) 199-207
    CrossrefPubMedGoogle Scholar
  • 202 Zanazzi G, Matthews G. The molecular architecture of ribbon presynaptic terminals.  Mol Neurobiol. 2009;  39 (2) 130-148
    CrossrefPubMedGoogle Scholar
  • 203 Fujino T, Watanabe K, Beppu M, Kikugawa K, Yasuda H. Identification of oxidized protein hydrolase of human erythrocytes as acylpeptide hydrolase.  Biochim Biophys Acta. 2000;  1478 (1) 102-112
    CrossrefPubMedGoogle Scholar
  • 204 Correll P H, Morrison A C, Lutz M A. Receptor tyrosine kinases and the regulation of macrophage activation.  J Leukoc Biol. 2004;  75 (5) 731-737
    PubMedGoogle Scholar
  • 205 Daig R, Andus T, Aschenbrenner E, Falk W, Schölmerich J, Gross V. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease.  Gut. 1996;  38 (2) 216-222
    CrossrefPubMedGoogle Scholar
  • 206 Buanne P, Di Carlo E, Caputi L et al.. Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice.  J Leukoc Biol. 2007;  82 (5) 1239-1246
    CrossrefPubMedGoogle Scholar
  • 207 Hsing A W, Sakoda L C, Rashid A et al.. Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China.  Cancer Res. 2008;  68 (15) 6442-6452
    CrossrefPubMedGoogle Scholar
  • 208 Dupuis-Girod S, Medioni J, Haddad E et al.. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients.  Pediatrics. 2003;  111 (5 Pt 1) e622-e627
    CrossrefPubMedGoogle Scholar
  • 209 Kahn K, Sharp H, Hunter D, Kerzner B, Jessurun J, Blaese M. Primary sclerosing cholangitis in Wiskott-Aldrich syndrome.  J Pediatr Gastroenterol Nutr. 2001;  32 (1) 95-99
    CrossrefPubMedGoogle Scholar
  • 210 Keitel V, Cupisti K, Ullmer C, Knoefel W T, Kubitz R, Häussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders.  Hepatology. 2009;  50 (3) 861-870
    CrossrefPubMedGoogle Scholar
  • 211 Bielig H, Zurek B, Kutsch A et al.. A function for AAMP in Nod2-mediated NF-kappaB activation.  Mol Immunol. 2009;  46 (13) 2647-2654
    CrossrefPubMedGoogle Scholar
  • 212 Hu L, Smith T F, Goldberger G. LFG: a candidate apoptosis regulatory gene family.  Apoptosis. 2009;  14 (11) 1255-1265
    CrossrefPubMedGoogle Scholar
  • 213 Zhao H, Ito A, Sakai N, Matsuzawa Y, Yamashita S, Nojima H. RECS1 is a negative regulator of matrix metalloproteinase-9 production and aged RECS1 knockout mice are prone to aortic dilation.  Circ J. 2006;  70 (5) 615-624
    CrossrefPubMedGoogle Scholar

Arthur KaserM.D. 

Division of Gastroenterology and Hepatology, Department of Medicine, University of Cambridge, Addenbrooke's Hospital

Hills Road, Cambridge CB2 0QQ, United Kingdom

Email: ak729@cam.ac.uk

      >